PHOTOCURE ASA NK-50
Research PHOTOCURE ASA NK-50 (PHS) on Bullrun: market cap EUR 126.64M, P/E 17.4. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPHS
- ExchangeF
- CountryNorway
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 126.64M
- P/E17.4
- Financial periodQ1 2026
- RevenueNOK 264.61M
- Net incomeNOK 83.42M
- Free cash flow-NOK 6.64M
- Gross margin96.1%
Valuation Snapshot
latest market cap is EUR 126.64M; P/E is 17.4.
Peer valuation comparison
Latest P/E is 17.43x versus a Healthcare sector median of 24.46x (28.8% below).
Latest P/E is 17.43x versus a Norway median of 15.32x (13.7% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2024 | NOK 525.39M | -NOK 3.34M | NOK 65.30M | 94.2% | -0.12 | NOK 293.85M | NOK 15.78M | NOK 501.72M |
| FY2023 | NOK 500.66M | NOK 979.00K | NOK 36.00M | 94.8% | 0.04 | NOK 259.50M | NOK 14.02M | NOK 482.85M |
| FY2022 | NOK 393.13M | -NOK 71.86M | -NOK 5.63M | 94.2% | -2.66 | NOK 268.07M | NOK 27.38M | NOK 462.73M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | EUR 126.64M | 17.4 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About PHOTOCURE ASA NK-50
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Cevira, a photodynamic drug-device combination product candidate for the non-surgical treatment of high-grade cervical dysplasia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is PHOTOCURE ASA NK-50's market cap?
PHOTOCURE ASA NK-50's market capitalization is EUR 126.64M.
What is PHOTOCURE ASA NK-50's P/E ratio?
PHOTOCURE ASA NK-50's price-to-earnings (P/E) ratio is 17.4.
What does PHOTOCURE ASA NK-50 do?
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Cevira, a photodynamic drug-device combination product candidate for the non-surgical treatment of high-grade cervical dysplasia.